Viridian Therapeutics, Inc. (VRDN) Income Statement
VRDN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsVRDN revenue and net income
Where VRDN's revenue goes
2025Each bar shows an amount and its share of revenue. VRDN kept −483.6% of revenue as net income.
VRDN profit margins
VRDN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +23,359.9% | +241.9% | +132.2% | +39.5% |
| Gross profit | +23,359.9% | +241.9% | — | +100.9% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
VRDN quarterly EPS vs estimates
Viridian Therapeutics beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 4, 2026 (estimate $-1.08).
VRDN income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70.8M | $302,000 | $314,000 | $1.8M | $3.0M | $1.1M | $4.5M | $8.4M | $4.0M | $3.3M |
| Cost of revenue | $1.2M | $1.2M | $1.3M | $755,000 | $620,000 | $28.3M | $32.8M | $30.4M | $19.6M | $2.5M |
| Gross profit | $70.8M | $302,000 | $314,000 | $1.8M | $3.0M | −$27.3M | $4.5M | −$22.0M | −$15.6M | $789,000 |
| Research & development | $338.9M | $238.3M | $159.8M | $100.9M | $56.9M | $28.3M | $34.8M | $30.4M | $19.6M | $888,000 |
| Sales, general & admin | $95.3M | $61.1M | $95.0M | $35.2M | $25.8M | $13.3M | $11.6M | $11.0M | $10.9M | $9.6M |
| Total operating expenses | $434.2M | $299.3M | $254.8M | $136.1M | $82.7M | $83.1M | $46.4M | $41.5M | $30.5M | $10.5M |
| Operating income | −$363.4M | −$299.0M | −$254.4M | −$134.3M | −$79.7M | −$110.4M | −$42.0M | −$33.1M | −$26.5M | −$12.5M |
| Interest income | $27.4M | $32.1M | $16.5M | $4.9M | $318,000 | $173,000 | $941,000 | $1.3M | $403,000 | — |
| Interest expense | $4.9M | $3.0M | $1.8M | $486,000 | $3,000 | $508,000 | $835,000 | $873,000 | $383,000 | $95,000 |
| Income before taxes | −$342.6M | −$269.9M | −$237.7M | −$129.9M | −$79.4M | −$110.7M | −$41.9M | −$32.7M | −$26.5M | −$12.7M |
| Income taxes | — | −$269.9M | $18.6M | −$4.4M | $3,000 | $269,000 | $547,000 | $1.3M | $95,000 | $95,000 |
| Net income | −$342.6M | −$269.9M | −$237.7M | −$129.9M | −$79.4M | −$110.7M | −$41.9M | −$32.7M | −$26.5M | −$12.7M |
| EBITDA | −$337.2M | −$266.4M | −$235.4M | −$129.1M | −$79.3M | −$40.3M | −$40.8M | −$31.5M | −$25.8M | −$12.5M |
| EPS (diluted) | −$3.29 | −$3.77 | −$5.32 | −$4.03 | −$7.69 | −$36.74 | −$20.10 | −$16.35 | −$22.50 | −$117.15 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | −2,595.6% | 100.0% | −262.8% | −390.2% | 23.6% |
| Operating margin | −512.9% | −99,018.2% | −81,035.0% | −7,579.2% | −2,690.8% | −10,512.4% | −941.0% | −394.5% | −662.8% | −374.8% |
| Net margin | −483.6% | −89,387.1% | −75,711.5% | −7,329.2% | −2,680.2% | −10,544.3% | −938.6% | −390.0% | −662.3% | −379.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $284,000 | $141,000 | $132,000 | $70.6M | $75,000 | $72,000 | $72,000 | $86,000 | $72,000 | $72,000 | $72,000 | $72,000 |
| Cost of revenue | $117,000 | $121,000 | $320,000 | $0 | $0 | $0 | $123,000 | $0 | $5.8M | $345,000 | $350,000 | $335,000 |
| Gross profit | $284,000 | $141,000 | −$188,000 | $70.6M | $75,000 | $72,000 | $72,000 | $86,000 | $72,000 | $72,000 | $72,000 | $72,000 |
| Research & development | $71.6M | $77.6M | $89.2M | $86.3M | $86.6M | $76.8M | $72.0M | $69.2M | $56.2M | $40.9M | $38.6M | $30.4M |
| Sales, general & admin | $55.0M | $38.7M | $33.7M | $24.3M | $20.2M | $17.1M | $15.6M | $14.4M | $16.1M | $15.0M | $33.0M | $20.9M |
| Total operating expenses | $126.6M | $116.3M | $122.6M | $110.6M | $106.8M | $93.9M | $87.5M | $83.6M | $72.3M | $56.0M | $71.5M | $51.3M |
| Operating income | −$126.3M | −$116.2M | −$122.7M | −$40.0M | −$106.8M | −$93.9M | −$87.5M | −$83.5M | −$72.2M | −$55.9M | −$71.5M | −$51.2M |
| Interest income | $8.5M | $7.9M | $7.8M | $5.5M | $6.5M | $7.5M | $8.6M | $7.8M | $7.8M | $7.9M | $5.5M | $4.2M |
| Interest expense | $8.3M | $3.5M | $6.6M | $560,000 | $514,000 | $586,000 | $858,000 | $1.0M | $597,000 | $587,000 | $916,000 | $600,000 |
| Income before taxes | −$127.1M | −$104.9M | −$120.4M | −$34.6M | −$100.7M | −$86.9M | −$79.7M | −$76.7M | −$65.0M | −$48.5M | −$66.9M | −$47.7M |
| Income taxes | — | — | — | — | — | — | — | — | $72.2M | −$145,000 | $5.5M | −$135,000 |
| Net income | −$127.1M | −$104.9M | −$120.4M | −$34.6M | −$100.7M | −$86.9M | −$79.7M | −$76.7M | −$65.0M | −$48.5M | −$66.9M | −$47.7M |
| EBITDA | −$118.7M | −$101.3M | −$113.6M | −$33.9M | −$100.1M | −$86.2M | −$78.7M | −$75.6M | −$64.3M | −$47.8M | −$65.8M | −$46.9M |
| EPS (diluted) | −$1.05 | −$0.90 | −$1.08 | −$0.34 | −$1.00 | −$0.87 | −$0.81 | −$1.15 | −$1.02 | −$0.79 | −$1.35 | −$1.09 |
| Gross margin | 100.0% | 100.0% | −142.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −44,460.6% | −82,389.4% | −92,991.7% | −56.7% | −142,356.0% | −130,369.4% | −121,488.9% | −97,069.8% | −100,259.7% | −77,634.7% | −99,275.0% | −71,144.4% |
| Net margin | −44,760.2% | −74,397.9% | −91,178.0% | −49.0% | −134,313.3% | −120,711.1% | −110,729.2% | −89,173.3% | −90,268.1% | −67,419.4% | −92,861.1% | −66,194.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in VRDN's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
VRDN financial results
In fiscal year 2025 (ended December 31, 2025), Viridian Therapeutics reported revenue of $70.8 million, up 23,359.9% from the year before. It had a net loss of $342.6 million, a net profit margin of −483.6%. Diluted earnings per share came to −$3.29. Over five years revenue grew at an average rate of 132.2% a year.
See the VRDN stock overview for the latest quote and news, or the VRDN chart for price history and technical indicators.
VRDN income statement FAQ
What is Viridian Therapeutics's annual revenue?
Viridian Therapeutics reported total revenue of $70.8 million for fiscal year 2025, which ended on December 31, 2025. That was up 23,359.9% from $0.3 million the previous year.
Is Viridian Therapeutics profitable?
No. Viridian Therapeutics reported a net loss of $342.6 million in fiscal 2025, a net profit margin of −483.6%; its operating margin was −512.9%.
What is Viridian Therapeutics's gross margin?
Viridian Therapeutics's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Viridian Therapeutics kept $100 after the direct cost of its products and services.
How much does Viridian Therapeutics spend on research and development?
Viridian Therapeutics spent $338.9 million on research and development in fiscal 2025, 478.4% of revenue.
How fast is Viridian Therapeutics growing?
Revenue grew 132.2% a year on average over the last five fiscal years, from $1.1 million to $70.8 million.
What are Viridian Therapeutics's earnings per share?
Viridian Therapeutics earned $-3.29 per diluted share in fiscal 2025, compared with $-3.77 a year earlier.
When will Viridian Therapeutics report its next earnings?
Viridian Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026.
When does Viridian Therapeutics's fiscal year end?
Viridian Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.